Revive Rx Can't End Eli Lilly's Suit Over Tirzepatide Drugs
A Texas federal judge has denied Revive Rx's bid to end Eli Lilly and Co.'s remaining unfair-competition claims over the compounding pharmacy's sales of allegedly unapproved tirzepatide weight-loss drugs that Eli...To view the full article, register now.
Already a subscriber? Click here to view full article